Scarica l'app Stockscreener
188.33
2.41%
-4.66
Dopo l'orario di chiusura:
188.33
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KRYS Giù?
Forum
Previsione
Precedente Chiudi:
$192.99
Aprire:
$193.41
Volume 24 ore:
239.55K
Relative Volume:
0.70
Capitalizzazione di mercato:
$5.45B
Reddito:
$290.51M
Utile/perdita netta:
$89.16M
Rapporto P/E:
62.99
EPS:
2.99
Flusso di cassa netto:
$119.18M
1 W Prestazione:
-0.23%
1M Prestazione:
+21.99%
6M Prestazione:
+14.35%
1 anno Prestazione:
+5.93%
Intervallo 1D:
$187.53
$195.91
Intervallo di 1 settimana:
$179.19
$195.91
Portata 52W:
$122.80
$207.84
Krystal Biotech Inc Stock (KRYS) Company Profile
Nome
Krystal Biotech Inc
Settore
Industria
Telefono
(412) 586-5830
Indirizzo
2100 WHARTON STREET, PITTSBURGH, PA
Confronta KRYS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
188.33 | 5.44B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-05 | Iniziato | Jefferies | Buy |
| 2024-08-06 | Downgrade | Citigroup | Buy → Neutral |
| 2023-11-20 | Iniziato | Goldman | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-10-12 | Iniziato | Citigroup | Buy |
| 2023-09-07 | Iniziato | Berenberg | Buy |
| 2023-04-18 | Iniziato | Stifel | Buy |
| 2023-02-28 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-25 | Downgrade | Goldman | Buy → Neutral |
| 2022-01-18 | Iniziato | BofA Securities | Buy |
| 2021-07-20 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-18 | Iniziato | B. Riley FBR | Buy |
| 2020-06-04 | Iniziato | Evercore ISI | Outperform |
| 2019-09-24 | Iniziato | Goldman | Neutral |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-24 | Reiterato | Chardan Capital Markets | Buy |
| 2019-06-24 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-30 | Iniziato | Guggenheim | Buy |
| 2018-09-11 | Iniziato | Cantor Fitzgerald | Overweight |
Mostra tutto
Krystal Biotech Inc Borsa (KRYS) Ultime notizie
Is Krystal Biotech Inc. stock safe for conservative investors2025 Earnings Surprises & Low Drawdown Investment Strategies - newser.com
Chart based analysis of Krystal Biotech Inc. trendsOil Prices & Weekly Watchlist for Consistent Profits - newser.com
Krystal Biotech Forms Golden Cross, Signaling Potential Bullish Breakout - Markets Mojo
What drives Krystal Biotech Inc stock priceMarket Liquidity Analysis & Free Stock Trading Workshops - earlytimes.in
Insider Confidence Shines: Krystal Biotech and Growth Stocks with Strong Management Stakes Navigate Volatile Markets - FinancialContent
Krystal Biotech And 2 More Growth Stocks With Significant Insider Ownership - Yahoo Finance
Krystal Biotech’s Neurotrophic Keratitis Gene Therapy Viral Vector Secures FDA Platform Technology Designation - CGTLive®
Krystal Biotech Inc. stock trend forecastWeekly Trade Summary & Technical Pattern Based Signals - newser.com
Is Krystal Biotech Inc. stock a safe buy before earningsMarket Trend Summary & Daily Stock Trend Reports - newser.com
Is Krystal Biotech Inc. meeting your algorithmic filter criteriaGlobal Markets & Expert Approved Trade Ideas - newser.com
FDA grants platform technology designation to Krystal Biotech’s HSV-1 vector - Investing.com Canada
FDA grants platform technology designation to Krystal Biotech’s HSV-1 vector By Investing.com - Investing.com South Africa
Krystal Biotech Gets US FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 - MarketScreener
FDA Grants Platform Technology Status to Krystal Biotech's Gene Therapy - GuruFocus
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis - The Manila Times
FDA Platform Designation: Krystal Biotech's HSV‑1 Viral Vector for KB801 to Advance Neurotrophic Keratitis Treatment - Stock Titan
Analyzing Krystal Biotech Inc. with risk reward ratio charts2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
What machine learning models say about Krystal Biotech Inc.2025 Valuation Update & Fast Exit and Entry Trade Guides - newser.com
Krystal Biotech (KRYS) Stock Analysis: A 13% Upside Potential Amid Strong Revenue Growth - DirectorsTalk Interviews
What valuation multiples suggest for Krystal Biotech Inc. stock2025 Trade Ideas & Consistent Growth Equity Picks - newser.com
Krystal Biotech Inc. stock outlook for YEARJuly 2025 Volume & Risk Managed Investment Signals - newser.com
Will Krystal Biotech Inc. (4KB) stock outperform Dow Jones2025 Buyback Activity & Consistent Profit Focused Trading Strategies - newser.com
Is Krystal Biotech Inc 4KB a good long term investmentCandlestick Trading Patterns & Budget Investment Success - earlytimes.in
I See Some Speculative Wins Starting to Krystal-ize - TheStreet Pro
What high frequency data says about Krystal Biotech Inc.2025 Momentum Check & Fast Gain Stock Tips - newser.com
Published on: 2025-10-10 04:55:37 - newser.com
What's Driving the Market Sentiment Around Krystal Biotech Inc? - Sahm
Market Participants Recognise Krystal Biotech, Inc.'s (NASDAQ:KRYS) Earnings Pushing Shares 29% Higher - simplywall.st
Sentiment analysis tools applied to Krystal Biotech Inc.Trade Exit Report & Technical Entry and Exit Alerts - newser.com
How Krystal Biotech Inc. stock reacts to Fed rate cutsCEO Change & AI Forecasted Entry/Exit Points - newser.com
Is Krystal Biotech Inc. (4KB) stock a buy for dividend portfoliosTrade Performance Summary & Growth Focused Stock Pick Reports - newser.com
How Krystal Biotech Inc. (4KB) stock reacts to monetary easingTrade Analysis Summary & Comprehensive Market Scan Insights - newser.com
Will Krystal Biotech Inc. (4KB) stock see valuation expansionTrend Reversal & Safe Capital Growth Trade Ideas - newser.com
What’s the recovery path for long term holders of Krystal Biotech Inc.Weekly Trading Summary & Community Verified Trade Signals - newser.com
Is Krystal Biotech Inc. (4KB) stock worth buying before Fed action2025 Dividend Review & Risk Managed Investment Strategies - newser.com
Krystal Biotech Hits Day High with 9.54% Surge in Strong Performance - Markets Mojo
Signal strength of Krystal Biotech Inc. stock in tech scannersJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com
Applying Elliott Wave Theory to Krystal Biotech Inc.Trade Risk Summary & Real-Time Chart Pattern Alerts - newser.com
Krystal Biotech Inc Azioni (KRYS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Krystal Biotech Inc Azioni (KRYS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Krishnan Suma | President, R&D |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Suma | President, R&D |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
| Krishnan Suma | President, R&D |
Jul 16 '25 |
Sale |
150.00 |
1,389 |
208,350 |
1,508,056 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,435 |
2,019,225 |
1,443,276 |
| Krishnan Krish S | President and CEO |
Jul 14 '25 |
Sale |
150.30 |
13,400 |
2,014,015 |
1,512,529 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
151.01 |
3,084 |
465,700 |
1,509,445 |
| Krishnan Krish S | President and CEO |
Jul 15 '25 |
Sale |
150.98 |
3,036 |
458,361 |
1,440,240 |
| Krishnan Krish S | President and CEO |
Jul 16 '25 |
Sale |
150.00 |
1,529 |
229,350 |
1,438,711 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):